Highest-materiality recent filing
Amgen CFO Peter Griffith retiring; Thomas Dittrich to succeed September 1, 2026
Peter Griffith retiring as EVP/CFO effective Aug 31, 2026; stays as non-executive EVP through Jan 2027.
Amgen Q1 2026 revenue $8.6B (+6% YoY), Non-GAAP EPS $5.15 (+5% YoY)
Total revenue $8.6B (+6% YoY); product sales grew 4% driven by 9% volume growth.
Amgen Q4 rev +9% to $9.9B; FY rev +10% to $36.8B; GAAP EPS $2.45, non-GAAP $21.84
Q4 total revenues $9.9B (+9% YoY); product sales +7% driven by 10% volume growth.
Amgen terminates rocatinlimab collaboration with Kyowa Kirin, effective upon HSR clearance
Termination agreement signed Jan 30, 2026 for 2021 License and Collaboration Agreement on rocatinlimab (KHK4083/AMG 451).
Amgen Q3 revenue up 12% to $9.6B, GAAP EPS $5.93, non-GAAP EPS $5.64
Revenue $9.6B (+12% YoY), product sales growth 12% on 14% volume growth, partially offset by 4% lower net price.
Amgen Q2 revenue $9.2B (+9% YoY); GAAP EPS $2.65 (+92%), non-GAAP EPS $6.02 (+21%)
Total revenues $9.2B, up 9% YoY; product sales up 9% on 13% volume growth, partially offset by 3% lower net selling price.
On May 19, 2026, Amgen Inc. (the “Company”) publicly announced that Peter H. Griffith will retire from the role of the Company’s Executive Vice President and Chief Financial Officer, effective August 31, 2026.
Effective September 1, 2026, he will serve as Executive Vice President and Chief Financial Officer of the Company.
Max materiality 0.85 · Median 0.62 · Most common event earnings